ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2018
Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04653831 (Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment With Pirfenidone for COVID-19 Related Severe ARDS An Open Label Pilot Trial
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Viral Pathogens and Pulmonary Fibrosis: EMT-Driven Mechanisms and Insights From Traditional Chinese Medicine.Reviews in medical virology · 2026Review
- Emerging highly pathogenic H5N1 influenza triggers fibrotic remodeling in human airway organoids.Emerging microbes & infections · 2025Article
- Novel insights into the ROCK-JAK-STAT signaling pathway in upper respiratory tract infections and neurodegenerative diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- The protein disulfide isomerase A3 and osteopontin axis promotes influenza-induced lung remodelling.British journal of pharmacology · 2024Article
- Beneficial effect of sequential treatment with high-dose steroids and short-course oral glucocorticoids in patients with severe influenza virus-associated pneumonia.Scientific reports · 2024Article
- Gene expression profile analysis of severe influenza-based modulation of idiopathic pulmonary fibrosis.European journal of medical research · 2024Article
- Influenza, SARS-CoV-2, and Their Impact on Chronic Lung Diseases and Fibrosis: Exploring Therapeutic Options.The American journal of pathology · 2024Review
- Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease.Journal of clinical medicine · 2023Article
- A Precise Method to Detect Post-COVID-19 Pulmonary Fibrosis Through Extreme Gradient Boosting.SN computer science · 2023Article
- Review
- Pulmonary Pathology of End-Stage COVID-19 Disease in Explanted Lungs and Outcomes After Lung Transplantation.American journal of clinical pathology · 2022Article
- Pulmonary Function and Chest Computed Tomography (CT) Scan Findings After Antifibrotic Treatment for COVID-19-Related Pulmonary Fibrosis.The American journal of case reports · 2022Article
- Respiratory Complications after COVID-19.Oman medical journal · 2022Review
- Virus infection induced pulmonary fibrosis.Journal of translational medicine · 2021Review
- Treatment of electronic cigarette or vaping product use-associated lung injury (EVALI) by corticosteroid and low-dose pirfenidone: Report of a case.Respirology case reports · 2021Article
- Surviving COVID-19: A Burden Yet to Come?Chest · 2021Article
- Post covid 19 pulmonary fibrosis. Is it real threat?The Indian journal of tuberculosis · 2021Review
- Pirfenidone: A novel hypothetical treatment for COVID-19.Medical hypotheses · 2020Article
- Pulmonary fibrosis in the aftermath of the COVID-19 era (Review).Experimental and therapeutic medicine · 2020Review
- The value of macrolides in the adjuvant treatment of pulmonary fibrosis: maybe a panacea.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are no specific data on the management of pulmonary fibrosis post-H1N1 ARDS. We present the cases of three patients who responded positively to treatment with pirfenidone, azithromycin and prednisolone. Three males, aged 40, 45 and 59 years, had H1N1 ARDS requiring mechanical ventilation for two weeks or longer. After weaning off ventilation, they had persistent symptoms and hypoxemia at rest despite receiving prednisolone and home oxygen for at least three weeks following discharge. Computed tomography (CT) of the chest showed fibrosis and traction bronchiectasis. At presentation, they could not perform spirometry. Investigations ruled out infection. Pirfenidone (600 mg daily escalated to maximum tolerable dose of 2.4 gm daily) and azithromycin (500 mg thrice weekly) were added off-label to prednisolone. In one patient pirfenidone was discontinued after three months due to an adverse reaction and azithromycin was continued for nine months. At one year follow-up, all patients had symptomatic improvement, better effort tolerance, regression of opacities and no progression of fibrosis on CT, and improvement in spirometry and six minute walk tests. Pirfenidone and azithromycin added to prednisolone may have led to clinical and radiological improvement. The current experience suggests that this treatment approach to pulmonary fibrosis post-H1N1 ARDS be studied further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.